BDR Pharmaceuticals launches India’s first generic Midostaurin (MSTARIN) for the treatment of Leukemia

~ Midostaurin is launched under the brand name MSTARIN and will be available in the strength of 25 mg~

Mumbai, December 07, 2021: BDR Pharma, one of India’s leading generic pharmaceutical companies, announced the launch of India’s first Generic- Midostaurin under the brand name MSTARIN, which is indicated in rare, hard-to-treat cancers. With the launch of generic Midostaurin (MSTARIN) in India, BDR is proud to deliver breakthrough medicine to patients with serious & hard-to-treat diseases at an affordable price compared to the cost of existing products in India.

The drug is approved for use in combination with standard Daunorubicin & Cytarabine induction & high- dose Cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.

AML (Acute Myeloid Leukemia) is the most common Leukemia or blood cancer in adults. It accounts for approximately 25% of all adult leukemia’s worldwide, with the highest incidence rates & also the lowest survival rates of all adult leukemia.

Marching towards the new milestone Mr. Raheel Shah, Director – Business Development, BDR Pharmaceuticals, said, “The birth of BDR Pharmaceuticals has taken place with a vision to provide healthcare to the Indian population at an affordable price and with the launch of the generic Midostaurin, patients with FLT3 mutated AML will now have access to this medicine at an affordable costs that could significantly extend their lives. The other most essential aspect to our business model is our strength of identifying and coming out with new molecules. This job is undertaken in our state of art Research and Development Centre located in Baroda which is well accredited”.

Those closely following global pharmas’ fight against the notorious coronavirus will have heard of BDR Pharmaceuticals. The Mumbai-based pharma company grabbed headlines throughout 2020-2021 for being a frontrunner in the race to manufacture drugs that fight the Coronavirus. When there was an urgent need for a self-reliant supply of the virus-fighting drugs in the country, the home-based company played a significant role in manufacturing Covid 19 drugs and made a whole basket of such drugs available for the Indian patients.

The drug will be available in the form of capsules.

Corporate Comm India (CCI Newswire)